Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Dr Fareeda Coxon

Newcastle AuthorsTitleYearFull text
Dr Fareeda Coxon
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): A prospective, randomised, double-blind, multicentre phase 2 trial2017
Dr Sari Alhasan
Dr Beate Haugk
Laura Ogle
Dr Gary Beale
Anna Long
et al.
Sulfatase-2: a prognostic biomarker and candidate therapeutic target in patients with pancreatic ductal adenocarcinoma2016
Dr Fareeda Coxon
Dr Kate Sumpter
Peri-operative chemotherapy +/- bevacizumab for resectable gastro-oesophageal adenocarcinoma: Results from the UK Medical Research Council randomised ST03 trial (ISRCTN 46020948)2015
Dr Fareeda Coxon
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): An open-label, phase 3 randomised controlled trial2014
Dr Fareeda Coxon
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial2014
Dr Fareeda Coxon
Dr Chris Plummer
Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report2013
Dr Fareeda Coxon
Dr Mario Abinun
Professor Andrew Cant
Identification of novel mutations in rankl as a cause of osteoclast-poor osteopetrosis2007
Dr Fareeda Coxon
The use of palliative protracted infusion 5FU (PVI 5FU) as first line treatment for metastatic oesophageal and gastric cancer patients not suitable for standard cisplatin based combination treatment2007
Dr Fareeda Coxon
Capecitabine (X) and oxaliplatin (O) combination chemotherapy in patients (pts) with advanced gall bladder or biliary tract cancer: A phase II study2006
Dr Fareeda Coxon
In vitro study of osteoclast phenotypes in different types of human osteopetrosis2006
12